Month: November 2024
New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints Excerpt from the Press Release: SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver…
Read More
Excerpt from the Press Release: HBI-3000 Aims to Fill Critical Gaps in Atrial Fibrillation Care; Key Data to be Presented at the American Heart Association Annual Meeting SAN DIEGO, Nov. 14, 2024 /PRNewswire/ — HUYABIO International today announced the presentation of new patient data for HBI-3000, an antiarrhythmic drug (AAD) with a unique protective profile for the treatment of atrial fibrillation (AF), one of the most common and serious heart conditions worldwide. This promising drug will be highlighted in a moderated poster presentation in the session entitled “The Return of Antiarrhythmic Drug Therapy: A New Age…
Read More
Data supporting the potential for innovative combinations like HBI-8000 and nivolumab to reshape the future of melanoma treatment will be presented at the Society for Immunotherapy of Cancer Annual Meeting Excerpt from the Press Release: SAN DIEGO, Nov. 8, 2024 /PRNewswire/ — HUYABIO International today announced it will present the final analysis of data from a phase…
Read More
Treatment with STK-012 monotherapy demonstrates dose-dependent induction of pro-inflammatory cytokines and selective proliferation of antigen-activated T cells, along with significant expansion of TCR clonality Company will also present new preclinical and GLP toxicology data on STK-026, its biased IL-12 partial agonist also designed for preferential activity on antigen-activated T cells Excerpt from the Press Release:…
Read More
NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at week 8 – – Pharmacodynamic data show NKTR-255 increased NK cell proliferation and markers of NK cell activation – Excerpt from the Press Release: SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR)…
Read More
Excerpt from the Press Release: LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today shared positive results from its Phase 1/2 dose escalation and cohort expansion study of AU-007. The data will be presented in a poster session at the Society for Immunotherapy of…
Read More
Meet with Christopher Kata, Director of Sales & Marketing December 3rd – 4th, 2024 at the Clinical Outsourcing Group CRO Summit Raleigh, NC! If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or just drop by booth at your convenience! We’re looking forward to providing live, personalized…
Read More
Recurrent low-grade serous ovarian cancer is a rare cancer with no FDA-approved treatments Company seeking accelerated approval and priority review of its NDA submission in patients with KRAS mutant low-grade serous ovarian cancer; FDA filing decision expected before the end of 2024 with potential for FDA approval decision by mid-2025 Excerpt from the Press Release:…
Read More
Late-breaking presentation highlights the pTau217 assay as an effective and efficient tool to screen participants for ALTITUDE-AD that reduces unnecessary amyloid PET scans and lumbar puncture procedures for those who are not eligible Excerpt from the Press Release: NEWTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company…
Read More
Efficacy signals observed will not achieve ESSA’s target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens A futility analysis conducted as part of a protocol-specified interim review of the safety, PK and efficacy data showed the single-agent enzalutamide control arm performing better than historical controls and similar to the combination…
Read More